首页>投融资
InflaRx
增发
InflaRx N.V.于2017年6月根据荷兰法律成立,根据公司重组的条款,该公司是一家InflaRx GmbH的控股的公司。该公司是一家临床阶段的生物制药公司,专注于应用其独有的反C5a技术来发现和开发一种名为C5a的补充激活因子的一级、有效和特异性抑制剂。C5a是一种强大的炎症介质,涉及多种自身免疫和其他炎症疾病的进展。
基本信息
-
公司全称Inflarx NV
-
类型单克隆抗体开发商
-
产业领域医药研发/制造
-
公司人数51~100人
-
地址Winzerlaer Str. 2 07745 Jena Germany
-
联系电话49-3641-508180
-
邮箱info@inflarx.de
-
成立时间2007-01-01
投融资
-
2023-04-18增发600万美元未透露
-
2023-04-14增发4000万美元未透露
-
2021-10-19IPO后其他轮次5070万美元未透露
-
2021-03-01增发7400万美元未透露
-
2017-11-08上市9300.465万美元未透露
-
2017-10-13D轮5500万美元鱼鹰资管Bain Capital
-
2016-07-21C轮3400万美元Staidson Hongkong Investment
-
2014-07-17B轮未透露bm-t beteiligungsmanagement thuringen
- 加载更多
相关投融资企业
战略投资
Medic Life Sciences Inc是一家美国的生物技术公司,专注于开发创新的医疗设备和诊断技术。公司致力于改善患者的诊断和治疗体验,通过提供高效、便捷的医疗产品和服务,满足医疗市场的需求。其主要产品线包括医疗影像设备、诊断试剂和生物信息学工具等,通过不断的技术创新和市场拓展,为全球患者带来更好的医疗健康
收并购
Alderley Analytical is an independent Contract Research Organisation (CRO). We offer specialist bioanalytical services to support your drug development programmes, from discovery through to late stage clinical development, focusing on small molecules, large molecules, peptides, biologics and biomarkers.
Our biotech, pharma and CRO clients have discovered that keeping their bioanalysis with one provider means fewer laboratory transfers and no loss of bioanalytical knowledge of the molecule. By simplifying this process, it means less complications helping the rapid development of new drugs.
We take a flexible and responsive approach, using our collective expertise to develop novel bioanalytical methods and deliver your results on-time to the right quality. We also pride ourselves on excellent communication; you’ll find us easy to get hold of and we stay in touch, even if there’s no news to report.
As a GLP and GCP accredited laboratory, we can offer regulatory compliance where needed and are able to validate bioanalytical methods and deliver bioanalytical results to current FDA/EMA guidelines. Get in touch to discuss your bioanalysis requirements today.
Visit our website at www.alderleyanalytical.com for more information.
增发
Theriva Biologics, Inc.成立于1986年,是一家生物技术公司,专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司,开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences,SL进入肿瘤学领域,VCN Biosciences,SL开发了一种新的溶瘤腺病毒平台,设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡,改善共同给药的癌症疗法对肿瘤的获取,并促进患者免疫系统产生强大而持续的抗肿瘤反应。